Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.

<h4>Background</h4>Drug resistance frequently led to the failure of chemotherapy for malignant cancers, hence causing cancer relapse. Thus, understanding mechanism of drug resistance in cancer is vital to improve the treatment efficacy. Here, we aim to evaluate the association between SM...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei Xu, Sau Har Lee, Fengjun Qiu, Li Zhou, Xiaoling Wang, Tingjie Ye, Xudong Hu
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/508cc21546b04f05a680a828a60b778b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:508cc21546b04f05a680a828a60b778b
record_format	dspace
spelling	oai:doaj.org-article:508cc21546b04f05a680a828a60b778b2021-12-02T20:05:27ZAssociation of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.1932-620310.1371/journal.pone.0250634https://doaj.org/article/508cc21546b04f05a680a828a60b778b2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0250634https://doaj.org/toc/1932-6203<h4>Background</h4>Drug resistance frequently led to the failure of chemotherapy for malignant cancers, hence causing cancer relapse. Thus, understanding mechanism of drug resistance in cancer is vital to improve the treatment efficacy. Here, we aim to evaluate the association between SMAD4 expression and the drug resistance in cancers by performing a meta-analysis.<h4>Method</h4>Relevant studies detecting SMAD4 expression in cancer patients treated with chemo-drugs up till December 2020 were systematically searched in four common scientific databases using selected keywords. The pooled hazard ratio (HR) was the ratio of hazard rate between SMAD4neg population vs SMAD4pos population. The HRs and risk ratios (RRs) with 95% confidence intervals (CIs) were used to explore the association between SMAD4 expression losses with drug resistance in cancers.<h4>Result</h4>After an initial screening according to the inclusion and exclusion criteria, eleven studies were included in the meta-analysis. There were a total of 2092 patients from all the included studies in this analysis. Results obtained indicated that loss of SMAD4 expression was significantly correlated with drug resistance with pooled HRs (95% CI) of 1.23 (1.01-1.45), metastasis with pooled RRs (95% CI) of 1.10 (0.97-1.25) and recurrence with pooled RRs (95% CI) of 1.32 (1.06-1.64). In the subgroup analysis, cancer type, drug type, sample size and antibody brand did not affect the significance of association between loss of SMAD4 expression and drug resistance. In addition, there was no evidence of publication bias as suggested by Begg's test.<h4>Conclusion</h4>Findings from our meta-analysis demonstrated that loss of SMAD4 expression was correlated with drug resistance, metastasis and recurrence. Therefore, SMAD4 expression could be potentially used as a molecular marker for cancer resistance.Wei XuSau Har LeeFengjun QiuLi ZhouXiaoling WangTingjie YeXudong HuPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0250634 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Wei Xu Sau Har Lee Fengjun Qiu Li Zhou Xiaoling Wang Tingjie Ye Xudong Hu Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.
description	<h4>Background</h4>Drug resistance frequently led to the failure of chemotherapy for malignant cancers, hence causing cancer relapse. Thus, understanding mechanism of drug resistance in cancer is vital to improve the treatment efficacy. Here, we aim to evaluate the association between SMAD4 expression and the drug resistance in cancers by performing a meta-analysis.<h4>Method</h4>Relevant studies detecting SMAD4 expression in cancer patients treated with chemo-drugs up till December 2020 were systematically searched in four common scientific databases using selected keywords. The pooled hazard ratio (HR) was the ratio of hazard rate between SMAD4neg population vs SMAD4pos population. The HRs and risk ratios (RRs) with 95% confidence intervals (CIs) were used to explore the association between SMAD4 expression losses with drug resistance in cancers.<h4>Result</h4>After an initial screening according to the inclusion and exclusion criteria, eleven studies were included in the meta-analysis. There were a total of 2092 patients from all the included studies in this analysis. Results obtained indicated that loss of SMAD4 expression was significantly correlated with drug resistance with pooled HRs (95% CI) of 1.23 (1.01-1.45), metastasis with pooled RRs (95% CI) of 1.10 (0.97-1.25) and recurrence with pooled RRs (95% CI) of 1.32 (1.06-1.64). In the subgroup analysis, cancer type, drug type, sample size and antibody brand did not affect the significance of association between loss of SMAD4 expression and drug resistance. In addition, there was no evidence of publication bias as suggested by Begg's test.<h4>Conclusion</h4>Findings from our meta-analysis demonstrated that loss of SMAD4 expression was correlated with drug resistance, metastasis and recurrence. Therefore, SMAD4 expression could be potentially used as a molecular marker for cancer resistance.
format	article
author	Wei Xu Sau Har Lee Fengjun Qiu Li Zhou Xiaoling Wang Tingjie Ye Xudong Hu
author_facet	Wei Xu Sau Har Lee Fengjun Qiu Li Zhou Xiaoling Wang Tingjie Ye Xudong Hu
author_sort	Wei Xu
title	Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.
title_short	Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.
title_full	Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.
title_fullStr	Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.
title_full_unstemmed	Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.
title_sort	association of smad4 loss with drug resistance in clinical cancer patients: a systematic meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/508cc21546b04f05a680a828a60b778b
work_keys_str_mv	AT weixu associationofsmad4losswithdrugresistanceinclinicalcancerpatientsasystematicmetaanalysis AT sauharlee associationofsmad4losswithdrugresistanceinclinicalcancerpatientsasystematicmetaanalysis AT fengjunqiu associationofsmad4losswithdrugresistanceinclinicalcancerpatientsasystematicmetaanalysis AT lizhou associationofsmad4losswithdrugresistanceinclinicalcancerpatientsasystematicmetaanalysis AT xiaolingwang associationofsmad4losswithdrugresistanceinclinicalcancerpatientsasystematicmetaanalysis AT tingjieye associationofsmad4losswithdrugresistanceinclinicalcancerpatientsasystematicmetaanalysis AT xudonghu associationofsmad4losswithdrugresistanceinclinicalcancerpatientsasystematicmetaanalysis
_version_	1718375479325491200

Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.

Ejemplares similares